Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Erastin and Ferroptosis: Mechanism, Evidence, Limits
2026-10-09
Erastin is a ferroptosis inducer used to examine redox collapse, lipid peroxidation, and genotype-linked tumor vulnerability. This evidence-focused guide connects its canonical mechanism with endothelial ferroptosis research while clarifying what the current literature does—and does not—establish.
-
Leucomycin (Kitasamycin): From Mechanism to Translation
2026-10-09
Leucomycin, or kitasamycin, is best understood not simply as a macrolide antibiotic, but as a compositionally complex research system linking ribosomal inhibition, cellular transport, resistance biology, and translational assay design. Historical biosynthesis data show why component identity and analytical context matter when interpreting antibacterial results.
-
Amitriptyline HCl Product Overview
2026-10-08
A concise, source-limited overview of Amitriptyline HCl, covering documented identity, supplier-reported specifications, conceptual research scope, and evidence limitations.
-
Live-Dead Cell Staining Kit: Evidence in Context
2026-10-08
Explore how the Live-Dead Cell Staining Kit can strengthen interpretation of biomaterial, cytotoxicity, and cell viability studies. This evidence-focused guide connects Calcein-AM Propidium Iodide staining with findings from a matrix metalloproteinase-responsive scaffold study while clarifying what viability data can—and cannot—prove.
-
BBB Permeability Modeling with Lysosomal Correction
2026-10-07
Hu and colleagues developed a high-throughput surrogate blood-brain barrier model that combines LLC-PK1-MOCK/MDR1 cells with permeability, efflux, recovery, and in vivo distribution analyses. Its key contribution is the explicit correction of lysosomal trapping, which improved interpretation for low-recovery compounds and strengthened the model’s value for early CNS drug screening.
-
D-Lin-MC3-DMA: Evidence and Research Context
2026-10-07
A source-grounded overview of D-Lin-MC3-DMA, covering its proposed role in lipid nanoparticle RNA delivery, reported hepatic gene-silencing findings, conceptual applications, evidence strength, and important limitations.
-
Proteinase K: Evidence, Mechanism and DNA Context
2026-10-06
Proteinase K is a broad-spectrum serine protease used for protein hydrolysis in molecular biology and enzyme contaminant removal for DNA prep. Product documentation supports broad biochemical compatibility, while a 2026 Candida albicans study provides separate evidence about extracellular-vesicle regulation of hyphal development.
-
IWR-1-endo in Wnt Signaling Research
2026-10-06
IWR-1-endo is a research small molecule used to interrogate canonical Wnt/β-catenin signaling. This overview separates supplier-reported mechanism and potency claims from evidence in the supplied literature, explains conceptual applications in colorectal cancer research, regeneration, and stem-cell biology, and examines limitations involving pathway context, model validity, compound specificity, and source provenance. The supplied HSBP7 cardiomyopathy preprint illustrates the value of combining morphological and functional readouts, but it does not test IWR-1-endo or establish a connection between Wnt inhibition and titin cardiomyopathy.
-
Epacadostat and IDO1: Evidence in Context
2026-10-05
Epacadostat, also known as INCB024360, is an IDO1-directed research compound investigated as a way to study tryptophan metabolism and immune regulation. The supplied evidence supports a mechanistic and assay-development rationale, but it does not establish clinical efficacy or directly evaluate Epacadostat in the cited whole-blood protocol. This overview compares the evidence levels, conceptual applications, and translational limitations.
-
Caspase-4 Colorimetric Assay Kit in ER-Stress Studies
2026-10-05
Explore how the Caspase-4 Colorimetric Assay Kit can add mechanistic resolution to pyroptosis and ER-stress research. This article distinguishes caspase-4 activity from broader cell-death outcomes and interprets the assay alongside findings from enzyme-instructed peptide self-assembly.
-
XFZYD in Chronic Migraine: Integrated Omics Evidence
2026-10-04
A 2026 study combines untargeted plasma metabolomics with brain-tissue transcriptomics to investigate how Xuefu Zhuyu Decoction affects a nitroglycerin-induced chronic migraine rat model. The findings prioritize MAPK/ERK signaling and connect XFZYD-associated molecular changes with vascular dysfunction, neurogenic inflammation, and stress-response biology, while remaining preclinical rather than clinical proof.
-
PreScission Protease: Product Overview
2026-10-03
PreScission Protease (PSP), supplied by APExBIO, is described as a recombinant HRV 3C protease–GST fusion intended for conceptual use in fusion protein tag cleavage. No matched paper evidence was provided, so product performance and workflow compatibility remain unverified here.
-
In Vitro Drug Responses: Growth Inhibition vs Cell Death
2026-10-02
Hannah R. Schwartz’s 2022 dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell killing are related but non-equivalent responses. The framework supports time-resolved assay design and more cautious interpretation of anticancer drug activity.
-
BBB Permeability Screening: Study Insights
2026-10-01
The 2025 reference study combines paired LLC-PK1-MOCK/MDR1 Transwell barriers with lysosomal trapping correction to improve high-throughput prediction of brain distribution. Its correlation with unbound brain partitioning and validation across structurally diverse compounds support a practical framework for separating passive diffusion, P-glycoprotein efflux, and intracellular sequestration.
-
EPZ5676: A Practical DOT1L Inhibitor Workflow
2026-10-01
EPZ5676 connects highly selective DOT1L inhibition with time-resolved H3K79 methylation and leukemia phenotyping. This workflow emphasizes solvent control, orthogonal target-engagement assays, and careful separation of direct evidence from cross-domain hypotheses.